Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
Trial details
- Registry ID
- NCT04596150
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast CancerNCT04596150 | CytomX Therapeutics | Phase 2 | Completed | 2023-06-02Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |